Manufacturer
BAXTER ONCOLOGY GMBH
Contents
213.8 mg cyclophosphamide monohydrate (equivalent to 200 mg anhydrous cyclophosphamide) as the active ingredient
Indication
ENDOXAN is used within a combination chemotherapy regimen or as monotherapy in Leukaemias:acute or chronic lymphocytic and myelogenous leukaemias
Malignant lymphomas:Hodgkin‘s disease, non-Hodgkin‘s lymphomas, plasmacytoma
Metastasizing and non-metastasizing malignant solid tumours:ovarian cancer, testicular cancer, breast cancer, small cell lung cancer, neuroblastoma, Ewing‘s sarcoma
Progressive “autoimmune diseases”:e.g.rheumatoid arthritis, psoriatic arthropathy, systemic lupus erythematosus, scleroderma, systemic vasculitides (e.g. with nephrotic
syndrome), certaintypes ofglomerulonephritis (e.g.with nephrotic syndrome),myastheniagravis, autoimmune haemolytic anaemia,
coldagglutinindiseases.: Immunosuppressive treatment in organ transplantations
Instruction
ENDOXAN should only be administered by experienced oncologists. The dosage must be adapted to each patient individually
Drug interaction
Planned coadministration or sequential administration of other substances or treatments that could increase the likelihood or severit y
of toxic effects (by means of pharmacodynamic or pharmacokinetic interactions) requires careful individual assessment of the
expected benefit and the risks. Patients receiving such combinations must be monitored closely for signs of toxicity to permit ti mely
intervention. Patients being treated with cyclophosphamide and agents that reduce its activation should be monitored for a po tential
reduction of therapeutic effectiveness and the need for dose adjustment.
Malaysia
